Eribulin mesylate demonstrated anti-tumor activity in patients with advanced breast cancer
In a Phase II clinical trial, eribulin mesylate demonstrated significant anti-tumor activity in heavily pretreated patients with locally advanced or metastatic breast cancer. The study showed an Overall Response Rate of 9.3% and a manageable tolerability profile with low incidence of Grade 3 and 4 neuropathy.